November 1, 2024 – Talk Bio

FDA Advisory Committee Rejects Lexicon’s Zynquista for Type 1 Diabetes and Chronic Kidney Disease

6 months ago talkbio0Tagged Advisory Committees, Chronic Kidney Diseases, Drug Approval, lexicon, United States Food and Drug Administration, Zynquista

FDA, Lexicon Pharmaceuticals, Zynquista, sotagliflozin, type 1 diabetes, chronic kidney disease, FDA advisory committee, drug approval

Merck’s Gardasil Sales in China Continue to Decline Amid Economic and Regulatory Challenges

6 months ago talkbio0Tagged China, Economics, Gardasil, Merck, regulatory issues, Vaccines

Merck, Gardasil, China, vaccine sales, economic challenges, regulatory issues

Jade Biosciences and Aerovate Therapeutics Announce Strategic Merger to Advance Autoimmune Disease Therapies

6 months ago talkbio0Tagged Autoimmune Diseases, Biosciences, Biotechnology, IGA Glomerulonephritis, paragon, reverse merger

Reverse merger, Jade Biosciences, Aerovate Therapeutics, Paragon Therapeutics, Autoimmune diseases, JADE-001, IgA nephropathy (IgAN), Biotechnology

Roche Advances Alzheimer’s Disease Diagnosis with Breakthrough Blood Test

6 months ago talkbio0Tagged Alzheimer 's disease, Amyloid, Diagnosis, Eli, Eli Lilly, Identifier, Medical Devices, Pathology, Roche, Roche (company), United States Food and Drug Administration

Alzheimer’s disease, blood test, Roche, Eli Lilly, FDA breakthrough device designation, pTau217, amyloid pathology, early diagnosis.

ESSA Pharma Terminates Masofaniten Development After Phase 2 Trial Failure in Prostate Cancer

6 months ago talkbio0Tagged Clinical Trial Termination, enzalutamide, ESSA, Malignant neoplasm of prostate, masofaniten, Pharma, Phase 2 trial

ESSA Pharma, Masofaniten, Prostate Cancer, Phase 2 Trial, Enzalutamide, Xtandi, Clinical Trial Termination

Novartis Secures First-Line Approval for Scemblix in Newly Diagnosed Chronic Myeloid Leukemia Patients

6 months ago talkbio0Tagged Approved, Diagnosis, First-Line Approval, Myeloid Leukemia, Chronic, Novartis, Scemblix, United States Food and Drug Administration

Scemblix, Novartis, first-line approval, chronic myeloid leukemia, CML, newly diagnosed, FDA approval

Merck Reports Strong Q3 Results but Lowers Full-Year Sales Guidance

6 months ago talkbio0Tagged Advice, Capvaxive, full-year, Gardasil, Januvia, Keytruda, Merck, results, Sales - occupational activity, Winrevair

Merck, Q3 Results, Full-Year Sales Guidance, Keytruda, Gardasil, Januvia, Winrevair, Capvaxive

Bristol Myers Squibb Posts Strong Q3 Results, Boosts 2024 Guidance on Robust Sales of Legacy and New Drugs

6 months ago talkbio0Tagged Advice, Drug Industry, earnings, financial performance, Inheritance, Myers, squibb

Bristol Myers Squibb, Q3 earnings, 2024 guidance, legacy drugs, newer drugs, pharmaceutical industry, financial performance

Biogen Raises Profit Guidance Amid Leqembi Growth and MS Sales Decline

6 months ago talkbio0Tagged Biogen, Drug Industry, earnings, Leqembi, Multiple Sclerosis, profit, Report (document)

Biogen, profit guidance, Leqembi, multiple sclerosis, earnings report, pharmaceutical industry

AbbVie and EvolveImmune Therapeutics Collaborate on Next-Generation Cancer Biotherapeutics Using T-Cell Engager Technology

6 months ago talkbio0Tagged AbbVie, Biological Factors, EvolveImmune, Immunotherapy, Next-Generation Cancer, Oncology Collaboration, T-Cell Engager Technology, Tumor cells, malignant

AbbVie, EvolveImmune Therapeutics, T-Cell Engager Technology, Next-Generation Cancer Biotherapeutics, Oncology Collaboration, Multispecific Biologics, Cancer Cell Resistance, Immunotherapies